Tokyo, April 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061304) titled 'Systemic SGLT2 Inhibition for Diabetic Macular Edema: A Scoping Review' on April 18.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - Kimitsu Chuo Hospital
Condition:
Condition - Diaetic Maclar Edema
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The purpose of this study is to evaluate the usefulness of SGLT2 inhibitors in diabetic macular edema through a scoping review.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Articles found on PubMed using the following search terms:
Diaetic Maclar Edema, Diaetic Maclar Oedema, Diabetic Retinopathy and SGLT2 inhibitor
Key exclusion criteria - Publications that do not mention diabetic macular edema
Publications concerning macular edema not caused by diabetic macular edema
Comments on the paper
Target Size - 20
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2026 Year 04 Month 01 Day
Date of IRB - 2026 Year 04 Month 01 Day
Anticipated trial start date - 2026 Year 04 Month 18 Day
Last follow-up date - 2026 Year 04 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070145
Disclaimer: Curated by HT Syndication.
